Separating Clinical and Subclinical Depression by Big Data Informed Structural Vulnerability Index and Its impact on Cognition: ENIGMA Dot Product

Peter Kochunov PhD¹ and Yizhou Ma PhD¹

1. Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA

Email: pkochunov@som.umaryland.edu and yizhou.ma@som.umaryland.edu

Kathryn S. Hatch BS¹, Lianne Schmaal PhD^{2,3}, Neda Jahanshad PhD⁴, Paul M. Thompson PhD⁴, Bhim M. Adhikari PhD¹, Heather Bruce MD¹, Joshua Chiappelli MD¹, Andrew Van der vaart MD, PhD¹, Eric L. Goldwaser DO, PhD¹, Aris Sotiras PhD³, Tianzhou Ma PhD⁶, Shuo Chen, PhD¹, Thomas E. Nichols PhD⁷, L. Elliot Hong MD¹

2. Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia

3. Orygen, Parkville, Australia

4. Imaging Genetics Center, Keck School of Medicine, Marina del Rey, CA, USA

5. Institute of Informatics, University of Washington, School of Medicine, St. Louis, Missouri, USA

6. Department of Epidemiology and Biostatistics, University of Maryland, College Park, MD, USA

7. Nuffield Department of Population Health of the University of Oxford, Oxford, United Kingdom.

Big Data neuroimaging collaborations including Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) integrated worldwide data to identify regional brain deficits in major depressive disorder (MDD). We evaluated the sensitivity of translating ENIGMA-defined MDD deficit patterns to the individual level. We treated ENIGMA MDD deficit patterns as a vector to gauge the similarity between individual and MDD patterns by calculating ENIGMA dot product (EDP). We analyzed the sensitivity and specificity of EDP in separating subjects with (1) subclinical depressive symptoms without a diagnosis of MDD, (2) single episode MDD, (3) recurrent MDD, and (4) controls free of neuropsychiatric disorders. We compared EDP to the Quantile Regression Index (QRI; a linear alternative to the brain age metric) and the global gray matter thickness and subcortical volumes and fractional anisotropy (FA) of water diffusion. We performed this analysis in a large epidemiological sample of UK Biobank (UKBB) participants (N=17,053/19,265 M/F). Group-average increases in depressive symptoms from controls to recurrent MDD was mirrored by EDP ($r^2=0.85$), followed by FA ($r^2=0.81$) and QRI ($r^2=0.56$). Subjects with MDD showed worse performance on cognitive tests than controls with deficits observed for 3 out of 9 cognitive tests administered by the UKBB. We calculated correlations of EDP and other brain indices with measures of cognitive performance in controls. The correlation pattern between EDP and cognition in controls was similar ($r^2=0.75$) to the pattern of cognitive differences in MDD. This suggests that the elevation in EDP, even in controls, is associated with cognitive performance - specifically in the MDD-affected domains. That specificity was missing for QRI, FA or other brain imaging indices. In summary, translating anatomically informed meta-analytic indices of similarity using a linear vector approach led to better sensitivity to depressive symptoms and cognitive patterns than whole-brain imaging measurements or an index of accelerated aging.

Keywords: Big data, meta-analysis, DTI, GM thickness, GM volume, structural deficit patterns, ENIGMA, EDP, depression, cognitive sequelae of depression

1. Introduction.

Major depressive disorder (MDD) is the most common of all severe mental illnesses affecting up to 20-30% of the worldwide population and inflicting a tremendous burden on patients, caregivers, and communities. The onset and course of MDD are influenced by genetic and environmental risk factors that are complex and remain poorly understood. Moreover, clinical and neuroimaging findings in MDD have historically been affected by heterogeneity and poor reproducibility (1). Collaborative studies by the Enhancing Neuro Imaging Genetics Meta Analyses (ENIGMA) led to a neuroimaging initiative to overcome the historically high heterogeneity and lack of consistent findings in MDD (2-8). The standardized workflows developed by ENIGMA made it possible to elucidate the imaging patterns associated with MDD in cohorts across the world. The inclusive worldwide nature of the collaboration has reduced site-specific variances and biases in diagnosis, inclusion and exclusion criteria, demographics medication, and environment. These concerted efforts yielded the discovery of deficit patterns that are shared by patients worldwide and remain present even after treatment with existing therapies.

In schizophrenia research, ENIGMA efforts led to the development of the similarity indices that use ENIGMA deficit patterns as the basis for vulnerability measurements (9). It is unknown, however, to what extent this approach can also be applied to MDD – specifically at different levels of severity including recurrent, single-episode, and subthreshold illness. It is also unclear if the better alignment with disordered patterns can explain variance in the cognition as cognitive deficits in MDD contribute to the burden of this disorder. Finally, it remains unclear if this approach distinguishes MDD groups better than multivariate metrics based on deviations from normative reference distributions (e.g., ‘brain age’ metrics) (10, 11). We design this study to answer two questions: A) is the similarity to the characteristic patterns of regional deficits derived by ENIGMA-MDD a better predictor of clinical features of depression, as compared to averaged brain structural measures? B) can the similarity index explain the cognitive variance in patients and non-psychiatric controls? We evaluated a linear algebra approach to calculate Enigma Dot Product (EDP) between the vector of individual brain structural measurements and the ENIGMA-derived patterns for MDD in the high-dimensional space of brain structural measurements. A larger EDP value suggests that the individual brain structural vector deviates from the expected population mean in the direction defined by the ENIGMA MDD deficit vector.

The neuroimaging structures used for the EDP calculation included 33 cortical thickness measures, 24 white matter diffusion tensor imaging (DTI) measures, and 7 subcortical gray matter volume measures. To compare EDP with traditional structural measures, we selected the whole-brain average measures including whole-brain average gray matter (GM) cortical thickness, subcortical GM volumes and fractional anisotropy (FA) of water diffusion. We also selected a Quantile Regression Index (QRI) - a linear analog of the BrainAge index that was shown to be sensitive to accelerated brain aging trends in MDD (12). We performed these analyses in the UK Biobank cohort which was chosen because it is the largest publicly available dataset with high-quality brain MRI scans. Notably, the UKBB participants were not included in the ENIGMA MDD studies and therefore it is an independent source of test data for the questions tackled here. We classified the UKBB participants into four subgroups that reflect severity of depression. These included (A) people who express some subclinical depression symptoms without a lifetime history of diagnosed MDD at the time of scan (B) people who had a single probable depressive episode, and (C) those who suffered from more than one episode of MDD (termed recurrent MDD). As a fourth comparison group, we also carefully chose a group of healthy controls (HC) who were free of any neurological or psychiatric disorders and denied significant depressive symptoms in their lifetime.

We hypothesized that alignment with expected MDD pattern would rise from controls to subclinical, single, and recurrent MDD. We tested if the group differences in EDP, the whole-brain averaged structural measures and accelerated aging index would provide the best predictions that are proportional to the group differences in symptoms. We further hypothesized that the EDP would predict subclinical cognitive deficits in individuals without a formal diagnosis of MDD better than the whole brain averaged structural measures. We examined a novel proposition that EDP can predict cognitive deficits in non-psychiatric controls, and specifically in

domains affected by MDD, and would do so better than the whole brain averaged structural measures. The overall goal of our study was to examine to what extent a linear combinatoric index of structural measures could be used to complement traditional structural measures and to provide an even more powerful approach to better understand the clinical differentiation and neurobiological underpinnings of different levels of depression.

2. Methods.

2.1 Participants

Neuroimaging and clinical data, including structural and diffusion imaging phenotypes, were available for N=37,285 individuals (17,082/20,203 M/F). Data were collected between 2012 and 2019 in participants recruited in the United Kingdom (13). All participants provided written informed consent.

2.2 Major Depressive Disorder Classification.

We classified participants into four subgroups of depression, i.e., subclinical depression without a current or lifetime MDD diagnosis (subclinical depression N=8,822; 4,313/4,509 M/F), single episode (N=1,147; 443/704 M/F), and recurrent MDD (N=8,089; 2,971/ 5,118 M/F) (Table 1). We integrated classification criteria previously published for participants' responses to the touchscreen questionnaire at each visit (Smith et al., 2013) with hospital records and self-reported diagnoses. Details of the classification are listed in Table 2. We took a conservative approach to defining controls so that participants with missing values (and thus preventing a definitive conclusion on certain criterion) were not used. We also excluded participants with significant neurological and psychiatric conditions (including bipolar disorder) and brain cancer per hospital records, self-report and probable bipolar disorder per (14).

We used the UKBB parser software (https://github.com/USC-IGC/ukbb_parser) to collect a group of N=7,266 (4,033/3,233 M/F, age = 63.3 ± 7.5) in the overall sample who were free of ICD codes corresponding to any neurological or psychiatric illnesses and major health conditions. The exclusion criteria included: bipolar disorder, schizophrenia, anxiety, Alzheimer's disease, head trauma, stroke, Parkinson's, PTSD, meningitis, multiple sclerosis, migraines, and other demyelinating diseases, cancer, heart disease, and were treated as non-neuropsychiatric controls (Table 1).

Table 1. Classification of participants into subgroups of depression and non-psychiatric controls.

MDD Classification	Number of Participants (M/F)	Average Age $\pm$ SD
Subclinical	8,822 (4,313/4,509)	63.6 ± 7.5
Single Episode	1,147 (443/704)	63.8 ± 7.4
Recurrent	8,089 (2,971/ 5,118)	62.1 ± 7.3
Controls	7,266 (4,033/3,233)	65.1 ± 7.5
Total	37285 (17082/20203)	63.6 ± 7.5

2.3 Imaging Protocol and Processing

In this study, we examined regional cortical gray matter thickness, subcortical gray matter structural volume and tract-wise measures of fractional anisotropy (FA) values provided by the UKBB. These phenotypes were extracted from neuroimaging data collected with Siemens Skyra 3T scanners using standard 32-channel radiofrequency (RF) head coils. The brain imaging protocol collected high resolution T1-weighted 3D MP-RAGE scans (resolution=1x1x1 mm, FOV=208x256x256, duration=5 minutes, sagittal, in-plane acceleration iPAT=2, prescan-normalize). Diffusion data were collected with a resolution of 2x2x2 mm and two diffusion shells of $b=1000$ and 2000 s/mm² with 50 diffusion directions per shell and 5 $b=0$ images (FOV=104x104x72, duration=7 minutes).

EDP calculations were based on the meta-analytical pattern aggregated from independent imaging studies of an illness to establish the 'gold standard' findings for that illness – here, the corresponding imaging measurements from ENIGMA were used. Accordingly, all imaging data were processed using the UKBB workflow that is based on the ENIGMA imaging processing pipelines. Details of the image preprocessing and analysis are

provided by UKBB (biobank.ctsu.ox.ac.uk/crystal/crystal/docs/brain_mri.pdf). Briefly, the UKBB workflow provides brain imaging measurements that have been evaluated across many ENIGMA studies. These phenotypes included 24 regional white matter tract FA values, 33 regional estimates of cortical gray matter (GM) thickness, volumes of the lateral ventricles, and 7 subcortical gray matter volumes per hemisphere that corresponded to those derived by ENIGMA workflows. Measures from the left and right structures were averaged.

2.4 Calculation of linear indices of similarity

All linear indices of vulnerability were calculated using the ‘RVlpkg’ implemented in [R] software in Kochunov et al. (2020). Briefly, the effects of age, sex, and the intracranial volume were regressed. The inverse-normal transformation was applied to the residuals. This produced a vector of Z-values for everyone, the absolute value of which was the deviation of the individual from the mean of the group. The EDP was calculated as the normalized dot product between P and E using the following equation.

$$DP = \frac{1}{N} \sum_{i=1}^N (P_i \times E_i)$$

Where P_i was the vector of deviation from the mean for the i -th phenotype and E_i was the vector of meta-analytical effect size for the i -th phenotype for MDD provided by ENIGMA. N was the total number of imaging phenotypes.

2.5 Calculation of QRI

Individual assessments of brain aging were performed using quantile regression analysis to derive a quantile regression index (QRI) score provided in the ‘QRlpkg’ for R (15) available for download at <https://CRAN.R-project.org/package=QRlpkg>. Briefly, the normative modeling technique provided a map of individual deviations from the expected aging trends using the whole sample. The QRI function used a quantile regression analysis with age serving as a predictor for cortical regional gray matter thickness, subcortical gray matter structure volumes, and white matter fractional anisotropy values to fit three separate models for the 5th, 50th, and 95th percentiles. Then, values for each individual subject were compared to the expected aging trajectory, derived from the whole sample, and each regional measure was assigned a score: values >95% of the expected age data were assigned a value of “-1”, indicating an individual’s actual brain age was significantly younger than what was expected for that age; values <5% received a value of “1”, indicating an individual’s actual brain age was significantly older than what was expected for that age; all others were assigned “0”. Regional scores were averaged for cortical thickness, subcortical volume, and white matter to create tissue specific QRIs. A whole-brain QRI was derived by averaging the three-tissue specific QRIs.

2.7 Cognitive assessment

Participants completed the automated UK Biobank cognitive test battery on a touchscreen computer (16). We included all tests collected by the UKBB covering cognitive domains of processing speed, cognitive flexibility, working memory, visuospatial learning/memory, perceptual reasoning, executive functioning/planning, and fluid intelligence.

2.8 Statistics

All statistical analyses were performed using RStudio v3.6.3 [71]. All measurements were preprocessed by correcting for age and sex prior to analysis. The relative effects of DP and other measurements on cognition were tested using the following model:

$$Cognition \sim \beta_{DP} \cdot DP + A \quad (1)$$

Where β was a linear predictor coefficient, and A was the intercept. Model 1 was used in controls to examine whether being merely similar to MDD in brain patterns was associated with poorer cognitive performance and whether the pattern of this association matched the cognitive differences between subjects with MDD and controls.

3. Results.

Figure 1. Symptom severity (0-4), EDP (normalized dot product), QRI (deviation from normal aging) and whole-brain measurements of gray matter (GM) thickness, subcortical volume and fractional anisotropy (FA) of water diffusion, expressed as normalized Z-scores after regressing age and sex effects were plotted for 4 groups – Controls (no evidence for MDD), Subclinical Depression, Single MDD Episode and Recurrent MDD groups.

($r^2=0.85$). In comparison, among the three whole-brain average indices, only the average FA value showed a pattern that agreed with the average symptoms for each group ($r^2=0.81$). Individual depressive symptoms in subjects with depression showed a significant correlation for EDP ($r=0.04$, $t=6.4$, $p=10^{-10}$), followed by average FA ($r=0.03$, $t=4.7$, $p=10^{-6}$) and QRI ($r=0.02$, $t=4.2$, $p=10^{-5}$) and but no significant correlation for GM thickness and volume.

3.2 Effects of MDD on cognition.

MDD was associated with lower cognitive function consistently across all MDD groups (Figure 2). Significant differences were observed for three out of nine tasks including Matrix, reaction time (RT) and Fluid Intelligence (Figure 2) compared to healthy controls.

3.3. Cognitive association.

We tested if the variance explained by a biomarker for each cognitive domain matched the pattern of clinical deficits in MDD subjects. In subjects with MDD, both EDP and GM thickness (GMT) matched ($r=0.90$ and 0.85 , $p<0.05$) the pattern of association observed in MDD vs. control group differences in cognitive measures (Figure 3). However, EDP explained a numerically higher degree of variance than GMT (average t -score = 3.1 ± 0.7 vs. 2.0 ± 0.8 , $p=0.04$). The other biomarkers did not show a significant correlation with the pattern of MDD-related

3.1 Group differences in symptoms and biomarkers.

The four subject groups demonstrated the expected difference in symptom severity (Figure 1). The ENIGMA dot product (EDP) showed the average values for four groups that were significantly higher in the clinical and subclinical depression groups than in controls (Figure 1). The average EDP values per group were correlated with the groups' average symptom severity

Figure 2. The pattern of cognitive differences (t-score) for subjects with MDD vs. controls. Significance is shown for the whole group vs. control analyses (yellow bars).

Figure 3. The scatter plots of the T-scores for the MDD vs. Control differences in 9 cognitive domains (Matrix, Reaction Time (RT), Numeric Memory (NM), Pairs Match (PM), Trails 1 and 2 (T1 and T2), Symbol Digit (SD), Tower (T), Fluid Intelligence (FI)) plotted versus T-scores for Model 1 predicting cognitive differences in participants affected with MDD.

cognitive deficits. We repeated the analysis in the controls. The t-scores of DP and GM thickness in model 1 for controls were significantly correlated with the t-scores of the MDD-control group differences ($r=0.84$ and 0.82 , $p<0.05$, for DP and GM thickness, respectively) (Figure 4). Likewise, the EDP explained a higher overall

Figure 4. The scatter plots of T-scores for MDD vs. Control differences in 9 cognitive domains (Matrix, Reaction Time (RT), Numeric Memory (NM), Pairs Match (PM), Trails 1 and 2 (T1 and T2), Symbol Digit (SD), Tower (T), Fluid Intelligence (FI)) plotted versus T-scores for Model 1 predicting cognitive differences in normal controls.

proportion of the cognitive variance than GMT (average t-score = 3.6 ± 0.7 vs. 1.9 ± 0.8 , $p=0.02$). There were no significant correlations for t-scores for QRI or FA or GM volume (Figure 4).

4. Discussion.

Using a large and inclusive dataset we evaluated the sensitivity and specificity of the ENIGMA Dop Product (EDP) index as a measurement of individual brain vulnerability for Major Depressive Disorder (MDD). EDP was calculated as a dot product between the vector of ENIGMA-MDD meta-analytic deficit values and an individual's phenotypic vector of z scores. Higher EDP scores indicated a combination of more deviations from the expected mean and better alignment with the ENIGMA-MDD pattern. We evaluated the sensitivity and specificity of EDP to disorder severity and cognitive deficits and compared it to an index of accelerated aging (QRI) as well as whole-brain average values for gray matter (GM) thickness and volumes and fractional anisotropy (FA) of water diffusion. The EDP was superior to QRI and whole-brain measurements in separating participants with different states of MDD and healthy controls and showed the strongest association with symptoms of depression in subjects with MDD. The higher EDP values were associated with poorer performance on cognitive tasks in the MDD group. The associations were stronger in cognitive tests affected by MDD. Repeating these analyses in controls demonstrated a similar trend, suggesting that EDP is also applicable to individuals free of depression and the EDP is sensitive to cognitive performance in healthy individuals. Overall, the novel vulnerability construct, EDP, shows the ability to transfer big data neuroimaging findings to the individual and can characterize vulnerability to MDD and deficits in cognitive performance, even in non-psychiatric individuals.

Big Data neuroimaging studies have markedly improved the stability of research findings in MDD (17, 18). The ENIGMA-MDD workgroup published regional deficit patterns that were replicable across independent datasets, including the UKBB (9). Here, we performed a head-to-head comparison to demonstrate the applicability of EDP in MDD research and its superiority to other measurements including measures of accelerated aging and whole-brain average neuroimaging measurements. The EDP showed a superior ability to separate subjects with MDD based on the severity of their illness compared to all other measurements that we selected. The EDP index showed a gradual increase from controls, to subjects with subclinical MDD, to MDD and recurrent MDD. Among all neuroimaging indices, only the average FA of cerebral white matter showed an intergroup pattern that matched that. However, EDP showed a more statistically significant intergroup difference than the average FA and a stronger association with symptoms in individual subjects than FA. The follow up analyses demonstrated that while the average FA was sensitive to the symptom severity, it did not track the cognitive deficits in MDD.

To further understand the roles of EDP on specificity to MDD, we used it to explain cognitive variance in subjects with MDD and normal controls. EDP tracks similarity to brain structural patterns and therefore incorporates both genetic and developmental risk factors associated with MDD and may provide the ability to characterize the potential vulnerability for cognitive impairments in both people affected with MDD and non-psychiatric controls. Cognitive deficits are not a substantial part of the diagnostic criteria for MDD but they are prominent beyond the potential 'impaired concentration' criterion and are debilitating features that contribute to the socioeconomic burden (19). In the UKBB sample, subjects with MDD performed significantly more poorly than controls on the Matrix, Reaction Time and Fluid Intelligence measures - consistent with the 'mental fog' reported in MDD patients (20). The EDP has readily replicated that pattern of association, while the pattern for other indices - except for GM thickness - did not match that of MDD. Specifically, FA and QRI selectively explained variance in the cognitive tests sensitive to information processing speed and working memory, while GM volume was not significantly associated with cognitive performance. The cortical GM thickness explained cognitive variance in a matching pattern. This was surprising because subjects with MDD did not demonstrate significant differences in whole-brain GM thickness, nor did this biomarker show an association with symptom severity (6).

We further tested the specificity of cognitive association by repeating this analysis in controls. Our hypothesis was that people in the general population that show similarity in brain metrics, as indexed by EDP, may be at higher risk for subtle cognitive deficits. We found that higher EDP values in non-neuropsychiatric subjects were significantly and inversely associated with cognitive performance in all nine cognitive measures. The EDP was especially sensitive to and explained more variance in the cognitive tests affected by MDD. The association between EDP and cognition matched the profile of cognitive deficits in MDD ($r=0.84$). The cortical GM thickness was likewise associated with cognitive performance in a similar pattern. Even so, the degree of variance that it explained in either subjects with MDD or controls was significantly smaller than that explained by EDP.

This study has several limitations. The diagnostic information provided in the UKBB is based on self-report and hospital records, but is not verified by independent clinical interviews, and thus is subject to some misclassification error (24). The study is also limited as it is based on the existing UKBB sample which is cross-sectional. Expansion of these large data sets into different phases of life as well as still other brain diseases would allow for improvement upon the proposed validity of these indices.

5. Conclusion

The ENIGMA Dot Product is a novel anatomically informed index of vulnerability that is calculated as a similarity index between an individual's brain patterns and expected patterns of deficits in cortical, subcortical, and white matter reported by the ENIGMA consortium. We found that higher EDP were associated with more severe symptoms of depression in subjects with MDD and with lower cognitive performance in psychiatrically healthy controls, in a pattern mirroring that observed in subjects with MDD. Indexing the similarity to brain imaging phenotypic patterns reported by big data neuroimaging studies of psychiatric conditions provides a characterization of the vulnerability to severe mental illnesses.

6. Acknowledgement. This work was supported by the National Institutes of Health grants R01MH112180, R01MH116948, S10OD023696, R01EB015611, R01MH117601, R01AG095874, R01MH116147, and U01MH108148. These funding sources provided financial support to enable design and conduct of the study or collection, management, or analysis of the data. LS is supported by a NHMRC Career Development Fellowship (1140764) and a University of Melbourne Dame Kate Campbell fellowship. None of the funding agencies had a role in the interpretation of the data. None had a role in the preparation, review, or approval of the manuscript. None had a role in the decision to submit the manuscript for publication.

References

1. Ioannidis JPA. How to Make More Published Research True. *PLoS medicine*. 2014;11:e1001747.
2. Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D, van Veen T, Willemsen G, DeRijk RH, de Geus EJ, Hoogendijk WJ, Sullivan PF, Penninx BW, Boomsma DI, Snieder H, Nolen WA. Poor replication of candidate genes for major depressive disorder using genome-wide association data. *Molecular Psychiatry*. 2011;16:516-532.
3. Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff RA, O'Donovan MC, Corvin A, Cichon S, Sullivan PF. Evaluating historical candidate genes for schizophrenia. *Molecular Psychiatry*. 2015;20:555-562.
4. van Erp TGM, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA, Agartz I, Westlye LT, Haukvik UK, Dale AM, Melle I, Hartberg CB, Gruber O, Kraemer B, Zilles D, Donohoe G, Kelly S, McDonald C, Morris DW, Cannon DM, Corvin A, Machielsen MWJ, Koenders L, de Haan L, Veltman DJ, Satterthwaite TD, Wolf DH, Gur RC, Gur RE, Potkin SG, Mathalon DH, Mueller BA, Preda A, Macciardi F, Ehrlich S, Walton E, Hass J, Calhoun VD, Bockholt HJ, Sponheim SR, Shoemaker JM, van Haren NEM, Pol HEH, Ophoff RA, Kahn RS, Roiz-Santiañez R, Crespo-Facorro B, Wang L, Alpert KI, Jönsson EG, Dimitrova R, Bois C, Whalley HC, McIntosh AM, Lawrie SM, Hashimoto R, Thompson PM, Turner JA. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Molecular psychiatry*. 2016;21:585.
5. van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, Pearlson GD, Yao N, Fukunaga M, Hashimoto R, Okada N, Yamamori H, Bustillo JR, Clark VP, Agartz I, Mueller BA, Cahn W, de Zwarte SMC, Hulshoff Pol HE, Kahn RS, Ophoff RA, van Haren NEM, Andreassen OA, Dale AM, Doan NT, Gurholt TP, Hartberg CB, Haukvik UK, Jorgensen KN, Lagerberg TV, Melle I, Westlye LT, Gruber O, Kraemer B, Richter A, Zilles D, Calhoun VD, Crespo-Facorro B, Roiz-Santianez R, Tordesillas-Gutierrez D, Loughland C, Carr VJ, Catts S, Cropley VL, Fullerton JM, Green MJ, Henskens FA, Jablensky A, Lenroot RK, Mowry BJ, Michie PT, Pantelis C, Quide Y, Schall U, Scott RJ, Cairns MJ, Seal M, Tooney PA, Rasser PE, Cooper G, Shannon Weickert C, Weickert TW, Morris DW, Hong E, Kochunov P, Beard LM, Gur RE, Gur RC, Satterthwaite TD, Wolf DH, Belger A, Brown GG, Ford JM, Macciardi F, Mathalon DH, O'Leary DS, Potkin SG, Preda A, Voyvodic J, Lim KO, McEwen S, Yang F, Tan Y, Tan S, Wang Z, Fan F, Chen J, Xiang H, Tang S, Guo H, Wan P, Wei D, Bockholt HJ, Ehrlich S, Wolthuisen RPF, King MD, Shoemaker JM, Sponheim SR, De Haan L, Koenders L, Machielsen MW, van Amelsvoort T, Veltman DJ, Assogna F, Banaj N, de Rossi P, Iorio M, Piras F, Spalletta G, McKenna PJ, Pomarol-Clotet E, Salvador R, Corvin A, Donohoe G, Kelly S, Whelan CD, Dickie EW, Rotenberg D, Voineskos AN, Ciufolini S, Radua J, Dazzan P, Murray R, Reis Marques T, Simmons A, Borgwardt S, Egloff L, Harrisberger F, Riecher-Rossler A, Smieskova R, Alpert KI, Wang L, Jonsson EG, Koops S, Sommer IEC, Bertolino A, Bonvino A, Di Giorgio A, Neilson E, Mayer AR, Stephen JM, Kwon JS, Yun JY, Cannon DM, McDonald C, Lebedeva I, Tomyshev AS, Akhadow T, Kaleda V, Fatouros-Bergman H, Flyckt L, Karolinska Schizophrenia P, Busatto GF, Rosa PGP, Serpa MH, Zanetti MV, Hoschl C, Skoch A, Spaniel F, Tomecek D, Hagenars SP, McIntosh AM, Whalley HC, Lawrie SM, Knochel C, Oertel-Knochel V, Stablein M, Howells FM, Stein DJ, Temmingh HS, Uhlmann A, Lopez-Jaramillo C, Dima D, McMahon A, Faskowitz JI, Gutman BA, Jahanshad N, Thompson PM, Turner JA. Cortical Brain Abnormalities in 4474

Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. *Biol Psychiatry*. 2018;84:644-654.

6. Schmaal L, Hibar DP, Samann PG, Hall GB, Baune BT, Jahanshad N, Cheung JW, van Erp TGM, Bos D, Ikram MA, Vernooij MW, Niessen WJ, Tiemeier H, Hofman A, Wittfeld K, Grabe HJ, Janowitz D, Bulow R, Selonke M, Volzke H, Grotegerd D, Dannlowski U, Arolt V, Opel N, Heindel W, Kugel H, Hoehn D, Czisch M, Couvy-Duchesne B, Renteria ME, Strike LT, Wright MJ, Mills NT, de Zubicaray GI, McMahon KL, Medland SE, Martin NG, Gillespie NA, Goya-Maldonado R, Gruber O, Kramer B, Hatton SN, Lagopoulos J, Hickie IB, Frodl T, Carballo A, Frey EM, van Velzen LS, Penninx B, van Tol MJ, van der Wee NJ, Davey CG, Harrison BJ, Mwangi B, Cao B, Soares JC, Veer IM, Walter H, Schoepf D, Zurowski B, Konrad C, Schramm E, Normann C, Schnell K, Sacchet MD, Gotlib IH, MacQueen GM, Godlewska BR, Nickson T, McIntosh AM, Pappmeyer M, Whalley HC, Hall J, Sussmann JE, Li M, Walter M, Aftanas L, Brack I, Bokhan NA, Thompson PM, Veltman DJ. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. *Mol Psychiatry*. 2017;22:900-909.

7. Schmaal L, Veltman DJ, van Erp TG, Samann PG, Frodl T, Jahanshad N, Loehrer E, Tiemeier H, Hofman A, Niessen WJ, Vernooij MW, Ikram MA, Wittfeld K, Grabe HJ, Block A, Hegenscheid K, Volzke H, Hoehn D, Czisch M, Lagopoulos J, Hatton SN, Hickie IB, Goya-Maldonado R, Kramer B, Gruber O, Couvy-Duchesne B, Renteria ME, Strike LT, Mills NT, de Zubicaray GI, McMahon KL, Medland SE, Martin NG, Gillespie NA, Wright MJ, Hall GB, MacQueen GM, Frey EM, Carballo A, van Velzen LS, van Tol MJ, van der Wee NJ, Veer IM, Walter H, Schnell K, Schramm E, Normann C, Schoepf D, Konrad C, Zurowski B, Nickson T, McIntosh AM, Pappmeyer M, Whalley HC, Sussmann JE, Godlewska BR, Cowen PJ, Fischer FH, Rose M, Penninx BW, Thompson PM, Hibar DP. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. *Mol Psychiatry*. 2016;21:806-812.

8. Kelly S, Jahanshad N, Zalesky A, Kochunov P, Agartz I, Alloza C, Andreassen OA, Arango C, Banaj N, Bouix S, Bousman CA, Brouwer RM, Bruggemann J, Bustillo J, Cahn W, Calhoun V, Cannon D, Carr V, Catts S, Chen J, Chen JX, Chen X, Chiapponi C, Cho KK, Ciullo V, Corvin AS, Crespo-Facorro B, Cropley V, De Rossi P, Diaz-Caneja CM, Dickie EW, Ehrlich S, Fan FM, Faskowitz J, Fatouros-Bergman H, Flyckt L, Ford JM, Fouche JP, Fukunaga M, Gill M, Glahn DC, Gollub R, Goudzwaard ED, Guo H, Gur RE, Gur RC, Gurholt TP, Hashimoto R, Hatton SN, Henskens FA, Hibar DP, Hickie IB, Hong LE, Horacek J, Howells FM, Hulshoff Pol HE, Hyde CL, Isaev D, Jablensky A, Jansen PR, Janssen J, Jonsson EG, Jung LA, Kahn RS, Kikinis Z, Liu K, Klauser P, Knochel C, Kubicki M, Lagopoulos J, Langen C, Lawrie S, Lenroot RK, Lim KO, Lopez-Jaramillo C, Lyall A, Magnotta V, Mandl RCW, Mathalon DH, McCarley RW, McCarthy-Jones S, McDonald C, McEwen S, McIntosh A, Melicher T, Meshulam-Gately RI, Michie PT, Mowry B, Mueller BA, Newell DT, O'Donnell P, Oertel-Knochel V, Oestreich L, Paciga SA, Pantelis C, Pasternak O, Pearlson G, Pellicano GR, Pereira A, Pineda Zapata J, Piras F, Potkin SG, Preda A, Rasser PE, Roalf DR, Roiz R, Roos A, Rotenberg D, Satterthwaite TD, Savadjiev P, Schall U, Scott RJ, Seal ML, Seidman LJ, Shannon Weickert C, Whelan CD, Shenton ME, Kwon JS, Spalletta G, Spaniel F, Sprooten E, Stablein M, Stein DJ, Sundram S, Tan Y, Tan S, Tang S, Temmingh HS, Westlye LT, Tonnesen S, Tordesillas-Gutierrez D, Doan NT, Vaidya J, van Haren NEM, Vargas CD, Vecchio D, Velakoulis D, Voineskos A, Voyvodic JQ, Wang Z, Wan P, Wei D, Weickert TW, Whalley H, White T, Whitford TJ, Wojcik JD, Xiang H, Xie Z, Yamamori H,

Yang F, Yao N, Zhang G, Zhao J, van Erp TGM, Turner J, Thompson PM, Donohoe G.

Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. *Mol Psychiatry*. 2018;23:1261-1269.

9. Kochunov P, Fan F, Ryan MC, Hatch KS, Tan S, Jahandshad N, Thompson PM, Van Erp TGM, Turner J, Chen S, Du X, Adhikari BM, Bruce HA, Hare S, Goldwaser E, Kvarta M, Huang J, Tong J, Cui Y, Cao B, Tan Y, Hong LE. Translating ENIGMA Schizophrenia Findings Using the Regional Vulnerability Index: Association with Cognition, Symptoms and Disease Trajectory. *Human Brain Mapping*. 2020;In Press.

10. Han LKM, Dinga R, Hahn T, Ching CRK, Eyler LT, Aftanas L, Aghajani M, Aleman A, Baune BT, Berger K, Brak I, Filho GB, Carballido A, Connolly CG, Couvy-Duchesne B, Cullen KR, Dannlowski U, Davey CG, Dima D, Duran FLS, Enneking V, Filimonova E, Frenzel S, Frodl T, Fu CHY, Godlewska BR, Gotlib IH, Grabe HJ, Groenewold NA, Grotegerd D, Gruber O, Hall GB, Harrison BJ, Hatton SN, Hermesdorf M, Hickie IB, Ho TC, Hosten N, Jansen A, Kähler C, Kircher T, Klimes-Dougan B, Krämer B, Krug A, Lagopoulos J, Leenings R, MacMaster FP, MacQueen G, McIntosh A, McLellan Q, McMahon KL, Medland SE, Mueller BA, Mwangi B, Osipov E, Portella MJ, Pozzi E, Reneman L, Repple J, Rosa PGP, Sacchet MD, Sämann PG, Schnell K, Schranke A, Simulionyte E, Soares JC, Sommer J, Stein DJ, Steinsträter O, Strike LT, Thomopoulos SI, van Tol MJ, Veer IM, Vermeiren R, Walter H, van der Wee NJA, van der Werff SJA, Whalley H, Winter NR, Wittfeld K, Wright MJ, Wu MJ, Völzke H, Yang TT, Zannias V, de Zubicaray GI, Zunta-Soares GB, Abé C, Alda M, Andreassen OA, Bøen E, Bonnin CM, Canales-Rodriguez EJ, Cannon D, Caseras X, Chaim-Avancini TM, Elvsåshagen T, Favre P, Foley SF, Fullerton JM, Goikolea JM, Haarman BCM, Hajek T, Henry C, Houenou J, Howells FM, Ingvar M, Kuplicki R, Lafer B, Landén M, Machado-Vieira R, Malt UF, McDonald C, Mitchell PB, Nabulsi L, Otaduy MCG, Overs BJ, Polosan M, Pomarol-Clotet E, Radua J, Rive MM, Roberts G, Ruhe HG, Salvador R, Sarró S, Satterthwaite TD, Savitz J, Schene AH, Schofield PR, Serpa MH, Sim K, Soeiro-de-Souza MG, Sutherland AN, Temmingh HS, Timmons GM, Uhlmann A, Vieta E, Wolf DH, Zanetti MV, Jahanshad N, Thompson PM, Veltman DJ, Penninx B, Marquand AF, Cole JH, Schmaal L. Brain aging in major depressive disorder: results from the ENIGMA major depressive disorder working group. *Mol Psychiatry*. 2020.

11. Franke K, Gaser C. Ten Years of BrainAGE as a Neuroimaging Biomarker of Brain Aging: What Insights Have We Gained? *Frontiers in neurology*. 2019;10:789.

12. Ryan M, Hong E, Hatch KS, Chen S, Wang J, Goldwaser E, Jahandshad N, Nichols T, Thompson PM, Kochunov P. The Additive Impact of Metabolic Disorders and Psychiatric Illnesses on Accelerated Brain Aging. *Mol Psychiatry*. 2020;In Review.

13. Manolio TA, Weis BK, Cowie CC, Hoover RN, Hudson K, Kramer BS, Berg C, Collins R, Ewart W, Gaziano JM, Hirschfeld S, Marcus PM, Masys D, McCarty CA, McLaughlin J, Patel AV, Peakman T, Pedersen NL, Schaefer C, Scott JA, Sprosen T, Walport M, Collins FS. New Models for Large Prospective Studies: Is There a Better Way? *American Journal of Epidemiology*. 2012;175:859-866.

14. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, Gill JM, Roberts B, Gallacher J, Mackay D, Hotopf M, Deary I, Craddock N, Pell JP. Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. *PLoS One*. 2013;8:e75362.

15. Kochunov P, Gao S, Ryan M. QRIPkg: Quantile Regression Index Score. R package version 020. 2020.
16. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine*. 2015;12:e1001779.
17. Kochunov P, Hong LE, Dennis EL, Morey RA, Tate DF, Wilde EA, Logue M, Kelly S, Donohoe G, Favre P, Houenou J, Ching CRK, Holleran L, Andreassen OA, van Velzen LS, Schmaal L, Villalon-Reina JE, Bearden CE, Piras F, Spalletta G, van den Heuvel OA, Veltman DJ, Stein DJ, Ryan MC, Tan Y, van Erp TGM, Turner JA, Haddad L, Nir TM, Glahn DC, Thompson PM, Jahanshad N. ENIGMA-DTI: Translating reproducible white matter deficits into personalized vulnerability metrics in cross-diagnostic psychiatric research. *Hum Brain Mapp*. 2020.
18. Kochunov P, Thompson PM, Hong LE. Toward High Reproducibility and Accountable Heterogeneity in Schizophrenia ResearchToward High Reproducibility and Accountable Heterogeneity in Schizophrenia ResearchEditorial. *JAMA Psychiatry*. 2019.
19. Sheffield JM, Karcher NR, Barch DM. Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective. *Neuropsychology review*. 2018;28:509-533.
20. Zaninotto L, Guglielmo R, Calati R, Ioime L, Camardese G, Janiri L, Bria P, Serretti A. Cognitive markers of psychotic unipolar depression: a meta-analytic study. *Journal of affective disorders*. 2015;174:580-588.
21. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen N, Donnelly P, Marchini J. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562:203-209.